In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic ...
Apr 27, 2020
0
10
The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis. The drug is also in advanced ...
Mar 26, 2020
0
5
(HealthDay)—Amongpatients with multidrug-resistant HIV-1 infection who have limited therapy options, reductions in HIV-1 RNA level were significantly greater in those who received fostemsavir compared with placebo during ...
Mar 26, 2020
0
103
Amgen has agreed to acquire the global rights to Otezla, a drug used for the treatment of psoriasis and psoriatic arthritis, for $13.4 billion in cash, Bristol Myers Squibb said Monday.
Aug 26, 2019
0
2
People with rare cancers have been out of luck—not only do most lack good treatments but drug companies also don't pursue them because of small potential sales. Now, a federal study that pools these folks gives them strength ...
Apr 1, 2019
0
6
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators ...
Feb 15, 2019
0
2
Pharmaceutical giant Eli Lilly announced Monday it will acquire Loxo Oncology for around $8 billion, the latest big transaction aimed at developing and monetizing new treatments for cancer.
Jan 7, 2019
0
0
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve ...
Sep 19, 2018
0
1
A new drug can restore memories and connections between brain cells in mice with a model of Alzheimer's disease, a new Yale-led study suggests.
Jul 6, 2017
0
209
Scientists at the University of Liverpool have demonstrated that a drug for treating hepatitis B virus (HBV) could be mass-produced for only £24 ($36) per person per year, versus the current UK NHS price of £4,600, and ...
Apr 22, 2015
0
23
